In contrast, we observed significant increases in the proportions of cells expressing IFNγ, TNFα, or CD107a, and even more strikingly all three effector molecules, among the subset of CD8+ T cells directed against the tumor-specific AH1 antigen (AH1/H-2Ld tetramer positive cells) in tumors from mice treated with a combination of anti-PD-1 and anti-GARP:TGF-β1 WT or FcD mAbs, but not with either mAb alone (Fig. 5f and Supplementary Fig. 9). This evidence concerns the gene CD8A and neoplasm.